Skip to main navigation Skip to search Skip to main content

The Effects of Soy Products on Cardiovascular Risk Factors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Clinical Trials

  • Omid Asbaghi
  • , Damoon Ashtary-Larky
  • , Aya Mousa
  • , Mahnaz Rezaei Kelishadi
  • , Seyedeh Parisa Moosavian

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Previous studies have suggested that soy products may be beneficial for cardiometabolic health, but current evidence regarding their effects in type 2 diabetes (T2D) remains unclear. The aim of this systematic review and meta-Analysis was to determine the impact of soy product consumption on cardiovascular risk factors in patients with T2D. PubMed, Scopus, Embase, and the Cochrane library were systematically searched from inception to March 2021 using relevant keywords. All randomized controlled trials (RCTs) investigating the effects of soy product consumption on cardiovascular risk factors in patients with T2D were included. Meta-Analysis was performed using random-effects models and subgroup analysis was performed to explore variations by dose and baseline risk profile. A total of 22 trials with 867 participants were included in this meta-Analysis. Soy product consumption led to a significant reduction in serum concentrations of triglycerides (TGs) [weighted mean difference (WMD):-24.73 mg/dL; 95% CI:-37.49,-11.97], total cholesterol (WMD:-9.84 mg/dL; 95% CI:-15.07,-4.61), LDL cholesterol (WMD:-6.94 mg/dL; 95% CI:-11.71,-2.17), and C-reactive protein (WMD:-1.27 mg/L; 95% CI:-2.39,-0.16). In contrast, soy products had no effect on HDL cholesterol, fasting blood sugar (FBS), fasting insulin, glycated hemoglobin, HOMA-IR, systolic blood pressure (SBP) and diastolic blood pressure, or BMI (all P ≥ 0.05). In subgroup analyses, there was a significant reduction in FBS after soy consumption in patients with elevated baseline FBS (>126 mg/dL) and in those who received higher doses of soy intake (>30 g/d). Moreover, soy products decreased SBP in patients with baseline hypertension (>135 mm Hg). Our meta-Analysis suggests that soy product consumption may improve cardiovascular parameters in patients with T2D, particularly in individuals with poor baseline risk profiles. However, larger studies with longer durations and improved methodological quality are needed before firm conclusions can be reached.

Original languageEnglish
Pages (from-to)455-473
Number of pages19
JournalAdvances in Nutrition
Volume13
Issue number2
DOIs
Publication statusPublished - Mar 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • cardiovascular risk
  • diabetes
  • meta-Analysis
  • soy
  • systematic review

Cite this